NovoCure Ltd
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $655.4M | $605.2M | $509.3M | $537.8M | $535.0M |
| Gross profit | $488.5M | $468.0M | $381.1M | $423.0M | $420.2M |
| Operating income | -$153.8M | -$170.5M | -$232.9M | -$89.5M | -$44.3M |
| Operating expenses | $642.3M | $638.5M | $613.9M | $512.5M | $464.5M |
| Cost of revenue | $166.9M | $137.2M | $128.3M | $114.9M | $114.9M |
| Cash from operations | -$49.0M | -$26.4M | -$73.3M | $30.8M | $82.8M |
| Capital expenditure | $26.6M | $42.9M | $27.1M | $21.4M | $24.2M |
| Free cash flow | -$75.7M | -$69.2M | -$100.4M | $9.4M | $58.6M |
| Impairments | $4.9M | $1.2M | $493,000 | $955,000 | $649,000 |
| Total assets | $804.3M | $1.2B | $1.1B | $1.2B | $1.1B |
| Total liabilities | $463.9M | $880.6M | $783.6M | $750.5M | $729.0M |
Shares outstanding 115.8M · Free float 87.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.